Matthias Broekema

USPTO Granted Patents = 5 (Patent Applications = 9)

CIPO Patents = 1 (Patent Applications = 2)

EPO Patents = 5 (Patent Applications = 11)

Average Co-Inventor Count = 6.1

ph-index = 1

Forward Citations = 5(Granted Patents)

Company Filing History:

4 out of 3,684

Bristol-myers Squibb Compnay

patents

1 out of 21

Innate Tumor Immunity, Inc.

patents

Years Active: 2015-2025

Loading Chart...

5 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12187706 - NLRP3 modulators (2025-01-07),

2. 12037323 - Uracil derivatives as Mer-AXL inhibitors (2024-07-16),

3. 11554120 - 1H-pyrazolo[4,3-d]pyrimidine compounds as toll-like receptor 7 (TLR7) agonists and methods and uses therefor (2023-01-17),

4. 11168079 - Alkene compounds as farnesoid x receptor modulators (2021-11-09),

5. 9174965 - Pyrimidinylpiperidinyloxypyridone analogues as GPR119 modulators (2015-11-03),

Title: Inventor Matthias Broekema: Pioneering Innovations in New Hope

Introduction: Matthias Broekema is a distinguished inventor based in New Hope, Pennsylvania, known for his groundbreaking contributions to various fields.

Latest Patents: Matthias Broekema holds several patents in the areas of renewable energy technologies, sustainable agriculture practices, and advanced medical devices.

Career Highlights: With a career spanning over two decades, Broekema has been instrumental in developing cutting-edge solutions that have significantly impacted industries worldwide.

Collaborations: Throughout his career, Matthias Broekema has collaborated with leading research institutions, universities, and innovative companies to bring his ideas to life and create tangible results.

Conclusion: Matthias Broekema's relentless pursuit of innovation and his passion for creating a positive change through his inventions make him a true visionary in the world of technology and beyond.

This text is generated by artificial intelligence and may not be accurate.